Watson Pharmaceuticals acquired Andrx Corporation for approximately $1.9B in cash, financed in part through a $650M term loan, consolidating its US generics position and adding Andrx's difficult-to-replicate controlled-release formulations. The combination created the third-largest US generics company by prescriptions. The FTC required divestitures in 13 overlapping generic drug markets as a condition of closing.